Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
G250 + DTIn1
- Development stage
- Preclinical
- Lead developer
- Ludwig Cancer Research
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
G250 + DTIn1 is a bispecific monoclonal antibody (bsMAb) produced via quadroma technology, designed for pretargeted imaging and therapy of cancer, notably renal cell carcinoma (RCC)[1][3]. One arm targets the G250 antigen (carbonic anhydrase IX, CAIX) highly expressed on RCC cells, while the other recognizes the DTPA-In hapten via the DTIn-1 monoclonal antibody. In preclinical models, tumors are first pretargeted with the bsMAb, then subsequently targeted with radiolabeled haptens such as ^111^In-DTPA or radioiodinated DTPA-peptides. This strategy enables high tumor-to-background ratios for imaging or therapeutic radionuclide delivery, but is restricted by DTIn-1’s specificity for DTPA chelating indium (not ^90^Y or ^177^Lu).
- Other names
- bispecific antibody G250 x DTIn-1
02
Targets
CA9 (Carbonic anhydrase IX)
Beyond the preview
Go deeper on G250 + DTIn1.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on G250 + DTIn1.